Recruiting
Phase 2

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT03916627

Conditions

Non-small Cell Lung Cancer

Hepatocellular Carcinoma

Head and Neck Squamous Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemiplimab

Platinum Doublet

fianlimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information